All Topics

The U.S. Department of Justice and DEA have issued a landmark order rescheduling FDA-approved marijuana products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act.

On May 6, 2026, the U.S. Food and Drug Administration (FDA) announced the launch of its “One-Day Inspectional Assessment” pilot program, an initiative designed to conduct shorter, more targeted inspections at certain FDA-regulated facilities across all FDA product areas, including food, drugs, biologics, and medical products.

To sue for patent infringement, a plaintiff must have constitutional standing under Article III and statutory standing under 35 U.S.C. § 281. Clearing these hurdles is straightforward for patent owners—that is, unless they exclusively license their patents. Exclusive licenses can deprive patent owners of constitutional standing if the patent owner fails to retain sufficient exclusionary rights.